Publication Name	World Journal of Clinical Oncology
Manuscript ID	90334
Country	Spain

Received	2023-11-30 09:13
Peer-Review Started	2023-11-30 09:13
To Make the First Decision
Return for Revision	2024-01-06 07:10
Revised	2024-02-25 17:30
Second Decision	2024-04-08 02:45
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-04-08 06:30
Articles in Press	2024-04-08 06:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-04-26 10:18
Publish the Manuscript Online	2024-05-21 07:25

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Pembrolizumab autoimmune related diabetes: Moving forward, keep learning
Manuscript Source	Invited Manuscript
All Author List	Jose Angel Garcia, Diego Alcaraz, Esther Holgado and Felipe Couñago
Funding Agency and Grant Number
Corresponding Author	Jose Angel Garcia, MMed, Attending Doctor, Department of Medical Oncology, GenesisCare Spain-San Francisco de Asis University Hospital, Joaquin Costa 28, Madrid 28002, Spain. jose.garcia@genesiscare.es
Key Words	Immune checkpoints; Pembrolizumab; Immunotherapy; Side effects; Endocrine system; Diabetes mellitus
Core Tip	Pembrolizumab-induced type 1 diabetes mellitus is a rare and potentially serious adverse event of immunotherapy, with a significant number of cases debuting abruptly and in a state of diabetic ketoacidosis without clear predisposing factors. Further research and strict follow-up by oncologists are fundamental tools for prevention and early treatment focusing on reducing the morbidity and mortality associated with this side effect.
Publish Date	2024-05-21 07:25
Citation	<p>Garcia JA, Alcaraz D, Holgado E, Couñago F. Pembrolizumab autoimmune related diabetes: Moving forward, keep learning. <i>World J Clin Oncol</i> 2024; 15(5): 576-579</p>
URL	https://www.wjgnet.com/2218-4333/full/v15/i5/576.htm
DOI	https://dx.doi.org/10.5306/wjco.v15.i5.576

Full Article (PDF)	WJCO-15-576-with-cover.pdf
Manuscript File	90334_Auto_Edited-YJP.docx
Answering Reviewers	90334-Answering reviewers.pdf
Audio Core Tip	90334-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	90334-Conflict-of-interest statement.pdf
Copyright License Agreement	90334-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	90334-Language certificate.pdf
Peer-review Report	90334-Peer-review(s).pdf
Scientific Misconduct Check	90334-Bing-Li L-2.png
Scientific Editor Work List	90334-Scientific editor work list.pdf
CrossCheck Report	90334-CrossCheck.png
CrossCheck Report	90334-CrossCheck report.pdf